All In Biotech

Drug Trial Radar · NCT01618695

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Last checked: Nov 19, 2026Latest source record: Jul 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 940 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

940

Actual

Start

May 15, 2012

Primary completion

Sep 15, 2014

Study completion May 28, 2020

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Jun 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures

Conditions

  • Partial-onset Seizures

Interventions

  • PerampanelDrug

    Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day. Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day.

  • PlaceboDrug

    Core study: Week 0 to Week 18 Once daily placebo. Extension study: Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)Time frame: Baseline, Week 19

Locations

117 sites in 7 countries. Site status is shown where the registry gives one.

  • Facility #1

    Bedford Park, Australia

  • Facility #1

    Camperdown, Australia

  • Facility #1

    Clayton, Australia

  • Facility #1

    Fitzroy, Australia

  • Facility #1

    Heidelberg, Australia

  • Facility #1

    Melbourne, Australia

  • Facility #1

    Randwick, Australia

  • Facility #1

    Beijing, Beijing Municipality, China

  • Facility #1

    Chongqing, Chongqing Municipality, China

  • Facility #1

    Xiamen, Fujian, China

  • Facility #1

    Guangzhou, Guangdong, China

  • Facility #2

    Guangzhou, Guangdong, China

  • Facility #1

    Harbin, Heilongjiang, China

  • Facility #1

    Changchun, Jilin, China

  • Facility #1

    Xi'an, Shaanxi, China

  • Facility #2

    Xi'an, Shaanxi, China

  • Facility #3

    Xi'an, Shaanxi, China

  • Facility #1

    Taiyuan, Shan'xi, China

  • Facility #1

    Jinan, Shandong, China

  • Facility #2

    Jinan, Shandong, China

  • Facility #1

    Qingdao, Shandong, China

  • Facility #1

    Shanghai, Shanghai Municipality, China

  • Facility #2

    Shanghai, Shanghai Municipality, China

  • Facility #3

    Shanghai, Shanghai Municipality, China

  • Facility #1

    Chengdu, Sichuan, China

  • Facility #2

    Chengdu, Sichuan, China

  • Facility #1

    Tianjin, Tianjin Municipality, China

  • Facility #1

    Kunming, Yunnan, China

  • Facility #1

    Wenzhou, Zhejiang, China

  • Eisai Trial Site #1

    Akita, Japan

  • Eisai Trial Site #1

    Aomori, Japan

  • Eisai Trial Site #1

    Fukui, Japan

  • Eisai Trial Site #1

    Fukuoka, Japan

  • Eisai Trial Site #2

    Fukuoka, Japan

  • Eisai Trial Site #1

    Gifu, Japan

  • Eisai Trial Site #1

    Hiroshima, Japan

  • Eisai Trial Site #2

    Hiroshima, Japan

  • Eisai Trial Site #1

    Kagoshima, Japan

  • Eisai Trial Site #2

    Kagoshima, Japan

  • Eisai Trial Site #1

    Kumamoto, Japan

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.